Considering that the current clinical heavy ion radiotherapy is performed using carbon beams for the treatment of tumors in the pelvic region, suppression of radiation intestinal disorders by application of p53 modulators is expected to be a useful therapeutic strategy. This evidence concerns the gene TP53 and intestinal disorder.